ARTICLE | Product Development

What Moderna’s COVID-19 vaccine data does not say about protection

Parlays Phase I data for mRNA-1273 into $1.3 billion follow-on

May 19, 2020 1:49 AM UTC

While Moderna’s interim Phase I data showing its COVID-19 vaccine successfully induced neutralizing antibodies against SARS-CoV-2 in humans are encouraging, they are difficult to interpret without disclosure of the titers.

Moreover, until it is clear how different titers translate to levels of protection, it is hard to get an early read on whether and how much any vaccine is effective...

BCIQ Company Profiles

Moderna Inc.